+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
FEMALE
ID07340398

Phase II Study of Personalized Neoadjuvant Treatments Using Trastuzumab-rezetecan Plus Pertuzumab or Pyrotinib-Based Therapy for HER2-Positive Early Breast Cancer After Initial Dual HER2-Targeted Therapy

Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2026-01-21

200

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating personalized neoadjuvant treatment approaches for patients with HER2-positive early breast cancer. This phase II study focuses on adjusting treatment based on how well patients respond to an initial combination of dual HER2-targeted therapy and chemotherapy. The goal is to improve treatment effectiveness for those who do not respond well while reducing unnecessary side effects for those who do. All participants first receive dual HER2-targeted therapy combined with chemotherapy. After this initial phase, their tumor response is carefully assessed. Patients who respond well continue the same treatment, while those with a suboptimal response are switched to a stronger investigational therapy. This intensified treatment includes either trastuzumab-rezetecan plus pertuzumab or a regimen with pyrotinib combined with chemotherapy and HER2-targeted agents, following specific study guidelines. Throughout the study, participants undergo regular clinical and imaging assessments to evaluate tumor response and treatment safety. Researchers will measure the total pathological complete response rate after about 18 weeks and monitor safety and side effects for up to three years. Long-term outcomes like event-free survival will also be followed for approximately five years. The study aims to identify biomarkers linked to treatment response to help guide future personalized therapies.

CONDITIONS

Brief Title

Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer

Research Team

Y

Yiding Chen

Y

Yunxiang Zhou

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here